ENSYSCE BIOSCIENCES, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ENSYSCE BIOSCIENCES, INC. (ENSC) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.87 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- ENSYSCE BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.87K, a 97.94% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.74K, a 46.20% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $24.34K, a 19.27% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $45.86K, a 120.27% increase year-over-year.
- ENSYSCE BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $177.09K, a 59.94% increase from fiscal 2024.
- ENSYSCE BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $110.72K, a 87.41% decline from fiscal 2023.
- ENSYSCE BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $879.16K, a 68.15% decline from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.76M, a 2166.74% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.87K 10-Q · filed 2026-08-13 | $10.61K 10-Q · filed 2026-08-13 | $34.95K derived: sum of 3 quarters · filed 2026-08-13 | $80.81K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $8.74K 10-Q · filed 2026-05-15 | $33.08K derived: sum of 2 quarters · filed 2026-05-15 | $78.94K derived: sum of 3 quarters · filed 2026-05-15 | $169.58K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $24.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $70.20K derived: sum of 2 quarters · filed 2026-03-30 | $160.84K derived: sum of 3 quarters · filed 2026-08-13 | $177.09K 10-K · filed 2026-03-30 |
| 2025-09-30 | $45.86K 10-Q · filed 2025-11-14 | $136.50K derived: sum of 2 quarters · filed 2026-08-13 | $152.75K 10-Q · filed 2025-11-14 | $182.90K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $90.64K 10-Q · filed 2026-08-13 | $106.89K 10-Q · filed 2026-08-13 | $137.04K derived: sum of 3 quarters · filed 2026-08-13 | $157.86K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $16.25K 10-Q · filed 2026-05-15 | $46.40K derived: sum of 2 quarters · filed 2026-05-15 | $67.22K derived: sum of 3 quarters · filed 2026-05-15 | $93.77K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $30.15K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $50.97K derived: sum of 2 quarters · filed 2026-03-30 | $77.52K derived: sum of 3 quarters · filed 2026-03-30 | $110.72K 10-K · filed 2026-03-30 |
| 2024-09-30 | $20.82K 10-Q · filed 2025-11-14 | $47.37K derived: sum of 2 quarters · filed 2025-11-14 | $80.57K 10-Q · filed 2025-11-14 | $709.51K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $26.55K 10-Q · filed 2025-08-13 | $59.76K 10-Q · filed 2025-08-13 | $688.69K derived: sum of 3 quarters · filed 2025-08-13 | $744.37K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $33.21K 10-Q · filed 2025-05-13 | $662.14K derived: sum of 2 quarters · filed 2025-05-13 | $717.82K derived: sum of 3 quarters · filed 2025-05-13 | $795.23K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $628.94K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $684.61K derived: sum of 2 quarters · filed 2025-03-10 | $762.03K derived: sum of 3 quarters · filed 2025-03-10 | $879.16K 10-K · filed 2025-03-10 |
| 2023-09-30 | $55.67K 10-Q · filed 2024-11-12 | $133.09K derived: sum of 2 quarters · filed 2024-11-12 | $250.22K 10-Q · filed 2024-11-12 | $466.91K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $77.42K 10-Q · filed 2024-08-14 | $194.55K 10-Q · filed 2024-08-14 | $411.24K derived: sum of 3 quarters · filed 2024-08-14 | $568.38K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $117.13K 10-Q · filed 2024-05-13 | $333.82K derived: sum of 2 quarters · filed 2024-05-13 | $490.97K derived: sum of 3 quarters · filed 2024-05-13 | $786.55K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $216.69K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $373.83K derived: sum of 2 quarters · filed 2024-03-15 | $669.41K derived: sum of 3 quarters · filed 2024-03-15 | $2.76M 10-K · filed 2024-03-15 |
| 2022-09-30 | $157.15K 10-Q · filed 2023-11-09 | $452.73K derived: sum of 2 quarters · filed 2023-11-09 | $2.54M 10-Q · filed 2023-11-09 | $2.56M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $295.58K 10-Q · filed 2023-08-11 | $2.39M 10-Q · filed 2023-08-11 | $2.40M derived: sum of 3 quarters · filed 2023-08-11 | $2.43M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $2.09M 10-Q · filed 2023-05-15 | $2.11M derived: sum of 2 quarters · filed 2023-05-15 | $2.13M derived: sum of 3 quarters · filed 2023-05-15 | $2.17M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $16.74K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $41.57K derived: sum of 2 quarters · filed 2023-03-30 | $77.94K derived: sum of 3 quarters · filed 2023-03-30 | $121.76K 10-K · filed 2023-03-30 |
| 2021-09-30 | $24.83K 10-Q · filed 2022-11-14 | $61.21K derived: sum of 2 quarters · filed 2022-11-14 | $105.03K 10-Q · filed 2022-11-14 | $163.64K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $36.37K 10-Q · filed 2022-08-11 | $80.19K 10-Q · filed 2022-08-11 | $138.81K derived: sum of 3 quarters · filed 2022-08-11 | $190.32K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $43.82K 10-Q · filed 2022-05-12 | $102.44K derived: sum of 2 quarters · filed 2022-05-12 | $153.95K derived: sum of 3 quarters · filed 2022-05-12 | $190.01K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $58.62K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $110.13K derived: sum of 2 quarters · filed 2022-03-31 | $146.19K derived: sum of 3 quarters · filed 2022-03-31 | $178.68K 10-K · filed 2022-03-31 |
| 2020-09-30 | $51.51K 10-Q · filed 2021-11-15 | $87.58K derived: sum of 2 quarters · filed 2021-11-15 | $120.06K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $36.06K 10-Q · filed 2021-08-16 | $68.55K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |